Dipexium Pharmaceuticals, Inc. (NASDAQ:PLXP) CFO David Emerson Jorden acquired 32,727 shares of the business’s stock in a transaction on Wednesday, June 14th. The shares were bought at an average price of $6.88 per share, for a total transaction of $225,161.76. Following the acquisition, the chief financial officer now owns 151,913 shares in the company, valued at approximately $1,045,161.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Dipexium Pharmaceuticals, Inc. (NASDAQ:PLXP) traded up 5.74% during mid-day trading on Tuesday, reaching $6.45. The company’s stock had a trading volume of 5,769 shares. The company’s market cap is $28.27 million. Dipexium Pharmaceuticals, Inc. has a 12 month low of $5.60 and a 12 month high of $142.01. The stock’s 50 day moving average is $6.32 and its 200 day moving average is $9.71.

Dipexium Pharmaceuticals (NASDAQ:PLXP) last issued its earnings results on Monday, April 17th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.12) by $0.02.

TRADEMARK VIOLATION NOTICE: This news story was published by Daily Political and is the property of of Daily Political. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.dailypolitical.com/2017/06/20/david-emerson-jorden-buys-32727-shares-of-dipexium-pharmaceuticals-inc-plxp-stock.html.

About Dipexium Pharmaceuticals

PLx Pharma Inc, formerly Dipexium Pharmaceuticals, Inc, is a biopharmaceutical company. The Company is a late stage specialty pharmaceutical company focusing on commercializing its lead products: Aspertec 325 mg and Aspertec 81 mg (Aspertec). The Company’s products and technology includes PLxGuard delivery system, Aspertec 325 mg, PL1100/PL1200 Ibuprofen.

Receive News & Ratings for Dipexium Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dipexium Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.